Abstract
Abstract. Major depression disorder (MDD) affects a big population and causes disability and productivity loss worldwide. Yet, fast-onset, powerful cure with minor side effects is scant. Therefore, there is an urging need to examine the biological bases for MDD treatment to design novel antidepressants. The serotonin system in the brain has long been a hot spot for research in this field, leading to accumulating biochemical discoveries of specific serotonin receptors. In this review, we briefly summarized the serotonin hypothesis of MDD, then focused on the implication of serotonin 2A receptor (5-HT2AR) in MDD therapy. Latest genomic evidence of 5-HT2AR gene variations related to MDD was presented. 5-HT2AR antagonists and agonists with antidepressive effects and their possible mechanisms of action was discussed. Based on current understanding of the 5-HT2ARs involvement in MDD therapy, we enumerated several future directions for developing applicable 5-HT2AR-targeting MDD treatment.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call